Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention
Shamir R. Mehta, MD, FACC*,* and
Salim Yusuf, DPhil, FACC*
* Division of Cardiology, McMaster University and the Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
Manuscript received July 9, 2002;
accepted August 19, 2002.
*
Reprint requests and correspondence: Dr. Shamir R. Mehta, Hamilton Health Sciences, General Division, McMaster Clinic, 237 Barton Street East, Hamilton, Ontario, Canada, L8L 2X2.
smehta{at}mcmaster.ca
Platelets play a central role in both the short- and long-term manifestations of atherothrombosis. In acute coronary syndrome (ACS), there is a steep rise in cardiovascular events early, followed by an incremental rise in cardiovascular events over the long term. This long-term event rate is related to persistent platelet activation and thrombin generation. There is therefore a need to optimize both short- and long-term oral antiplatelet and antithrombotic strategies. The benefits of aspirin therapy, when administered early and continued over the long term, were demonstrated in several early randomized trials. The Antithrombotic Trialists’ Collaboration found a 46% reduction in vascular events with antiplatelet therapy (mostly aspirin). However, despite treatment with aspirin and proven therapies, recurrent events remain high. The adenosine diphosphate receptor antagonists, ticlopidine and clopidogrel, inhibit the early steps of platelet activation, degranulation, and release of prothrombotic and inflammatory mediators, while also preventing activation of the glycoprotein IIb/IIIa receptor. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated the benefits of aspirin plus clopidogrel in reducing major cardiovascular events (cardiovascular death, myocardial infarction [MI], and stroke reduced by 20%, p = 0.00009) in a broad range of patients with ACS when administered early and continued over the long term. The benefits emerge very rapidly after a 300 mg loading dose. For the large number of patients undergoing percutaneous coronary intervention in the CURE trial, there was a substantial risk reduction with clopidogrel pretreatment followed by long-term therapy (p < 0.002). This benefit was present, regardless of whether intervention was performed early or late. The significant benefits of aspirin and clopidogrel persist for the combined efficacy-safety end point of cardiovascular death, MI, stroke, or life-threatening bleeding when clopidogrel is started early, combined with aspirin and other standard therapies, and continued for up to one year.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | ACS | = acute coronary syndrome(s) | | ADP | = adenosine diphosphate | | CABG | = coronary artery bypass graft | | GP | = glycoprotein | | MI | = myocardial infarction | | NSTE | = non–ST-segment elevation | | PCI | = percutaneous coronary intervention | | PTCA | = percutaneous transluminal coronary angioplasty | | RR | = risk reduction |
|
This article has been cited by other articles:
|
|
|
|
 
D. Shimbo, W. Chaplin, S. Kuruvilla, L. T. Wasson, D. Abraham, and M. M. Burg
Hostility and Platelet Reactivity in Individuals Without a History of Cardiovascular Disease Events
Psychosom Med,
September 1, 2009;
71(7):
741 - 747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Ernest II, M. A. Heathman, and R. E. Wrishko
Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis
J. Clin. Pharmacol.,
August 1, 2009;
49(8):
973 - 983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Paniccia, E. Antonucci, N. Maggini, E. Romano, A. M. Gori, R. Marcucci, D. Prisco, and R. Abbate
Assessment of Platelet Function on Whole Blood by Multiple Electrode Aggregometry in High-Risk Patients With Coronary Artery Disease Receiving Antiplatelet Therapy
Am J Clin Pathol,
June 1, 2009;
131(6):
834 - 842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-F. Dai, P. Thajeb, C.-F. Tu, F.-T. Chiang, C.-H. Chen, R.-B. Yang, and J.-J. Chen
Plasma concentration of SCUBE1, a novel platelet protein, is elevated in patients with acute coronary syndrome and ischemic stroke.
J. Am. Coll. Cardiol.,
June 3, 2008;
51(22):
2173 - 2180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Novak and L. A. Szczech
Feast and Famine: Epidemiology and Clinical Trials in Chronic Kidney Disease
J. Am. Soc. Nephrol.,
January 1, 2008;
19(1):
2 - 4.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Wiviott, E. Braunwald, C. H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.-J. Neumann, D. Ardissino, S. De Servi, S. A. Murphy, et al.
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
N. Engl. J. Med.,
November 15, 2007;
357(20):
2001 - 2015.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Karjalainen, P. Porela, A. Ylitalo, S. Vikman, K. Nyman, M.-A. Vaittinen, T. J. Airaksinen, M. Niemela, T. Vahlberg, and K.E. J. Airaksinen
Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting
Eur. Heart J.,
March 2, 2007;
28(6):
726 - 732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone and H. D. Aronow
Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy
Mayo Clin. Proc.,
May 1, 2006;
81(5):
641 - 652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S J Walsh, M S Spence, D Crossman, and A A J Adgey
Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond
Heart,
September 1, 2005;
91(9):
1135 - 1140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Schomig, C. Schmitt, A. Dibra, J. Mehilli, C. Volmer, H. Schuhlen, J. Dirschinger, F. Dotzer, J. M. ten Berg, F.-J. Neumann, et al.
One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel
Eur. Heart J.,
July 2, 2005;
26(14):
1379 - 1384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Altman, A. Scazziota, S. Santoro, and C. Gonzalez
Abciximab Does Not Inhibit the Increase of Thrombin Generation Produced in Platelet-Rich Plasma In Vitro by Sodium Arachidonate or Tissue Factor
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2005;
11(3):
271 - 277.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Sanderson, J. Emery, T. Baglin, and A.-L. Kinmonth
Narrative Review: Aspirin Resistance and Its Clinical Implications
Ann Intern Med,
March 1, 2005;
142(5):
370 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Cox, N. S. Kleiman, D. A. Boyle, J. Aluri, L. G. Parchman, F. Holdbrook, and M. J. Fossler
Pharmacokinetics and Pharmacodynamics of Argatroban in Combination With a Platelet Glycoprotein IIB/IIIA Receptor Antagonist in Patients Undergoing Percutaneous Coronary Intervention
J. Clin. Pharmacol.,
September 1, 2004;
44(9):
981 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, G. Percoco, D. Barbieri, F. Ferrari, G. Guardigli, G. Parrinello, O. Soukhomovskaia, and R. Ferrari
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The advance trial
J. Am. Coll. Cardiol.,
July 7, 2004;
44(1):
14 - 19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lorrain, I. Lechaire, C. Gauffeny, R. Masson, N. Roome, J.-P. Herault, S. E. O'Connor, P. Schaeffer, and J.-M. Herbert
Effects of SanOrg123781A, a Synthetic Hexadecasaccharide, in a Mouse Model of Electrically Induced Carotid Artery Injury: Synergism with the Antiplatelet Agent Clopidogrel
J. Pharmacol. Exp. Ther.,
April 1, 2004;
309(1):
235 - 240.
[Abstract]
[Full Text]
|
|
|
|
